Why the study?
Patients with CKD face high risks of recurring thrombotic events after AMI, and it was hypothesized that they have further elevated PMPs and EMPs compared to non-CKD patients despite antithrombotic treatment.
Are concentrations of platelet- and endothelial-derived microparticles elevated in AMI patients with CKD compared to those without CKD?
Population
AMI patients with CKD and non-CKD controls
Comparison
CKD stages 4-5 vs CKD stage 3 vs non-CKD group H
Design
Descriptive study
Authors
Loading...
Elevated PMPs and EMPs in AMI patients with CKD may indicate heightened activation; hypothesis-generating for targeted therapies without practice change.
Are concentrations of platelet- and endothelial-derived microparticles elevated in AMI patients with CKD compared to those without CKD?
AMI patients with advanced CKD have significantly higher levels of circulating platelet- and endothelial-derived microparticles, suggesting persistent platelet and endothelial activation despite concurrent antithrombotic therapy.
Mörtberg et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: